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Abstract
Relaxin is a corpus-luteum produced protein hormone with vasodilatatory, anti-fibrotic, and angiogenic properties that are
opposite to angiotensin (Ang) II. We investigated whether or not relaxin ameliorates Ang II-induced target-organ damage.
We used double transgenic rats harboring both human renin and angiotensinogen genes (dTGR) that develop severe
hypertension, target-organ damage, and die untreated within 7–8 weeks. Recombinant relaxin at a low (26 mg/kg/d) and a
high dose (240 mg/kg/d) was given to 4 week-old dTGR and age-matched Sprague-Dawley rats (SD). Systolic blood pressure
increased progressively in untreated dTGRs from 16263 mmHg at week 5 to 22565 mmHg at week 7. Relaxin had no effect
on blood pressure whereas SD rats were normotensive (10661 mmHg). Untreated and relaxin-treated dTGR had similarly
severe cardiac hypertrophy indices. Relaxin did not ameliorate albuminuria and did not prevent matrix-protein deposition in
the heart and kidney in dTGR. Finally, relaxin treatment did not reduce mortality. These data suggest that pharmacological
doses of relaxin do not reverse severe effects of Ang II.
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Introduction
Relaxin is a small peptide hormone important in reproduction
and pregnancy that is encoded by the RLX gene [1]. During
pregnancy, relaxin is produced by the corpus luteum; the hormone
reaches a peak plasma concentration in the late first trimester and
at delivery. Relaxin mediates the hemodynamic changes that
occur during pregnancy, such as increased cardiac output,
increased renal blood flow, and increased arterial compliance.
Relaxin also relaxes pelvic ligaments and is believed to soften the
pubic symphysis. Relaxin has anti-inflammatory, anti-apoptotic,
vasodilatory, and anti-fibrotic properties [2–4]. Male RLX gene-
deficient mice showed cardiac fibrosis, ventricular stiffening, and
diastolic dysfunction, suggesting a protective role for relaxin in
these processes [5]. Relaxin also increases arterial compliance,
cardiac output, and renal blood flow, which are potentially
relevant to the treatment of acute heart failure [2–4]. In two recent
studies, a 48 h relaxin infusion in patients with acute heart failure
showed beneficial effects on post-discharge mortality [6,7]. A
potential role for relaxin in protecting from preeclampsia and the
implication that upregulation of the renin-angiotensin system
could play a role in that condition caused us to test the hypothesis
that relaxin could ameliorate Ang II-induced target-organ
damage[8–11]. We used the well-established double transgenic
human-angiotensinogen and human-renin rat model (dTGR) [12–
15]. At age 7 weeks, dTGR show striking cardiac hypertrophy
with fibrosis, severe diastolic dysfunction but preserved systolic
function, proteinuria, and renal fibrosis [12–15]. Large areas of
infarction are absent, markers of critical ischemia are negative,
only rare patchy areas of myocardial necrosis can be observed in
dTGR6. Ang II induces a sustained inflammatory response, which
is to a large extending responsible for the severe phenotype.
Blocking the Renin-Angiotensin System is very successful
approach in ameliorating target-organ damage in this model
[16], but several anti-inflammatory strategies, such as high dose
aspirin, TNF-receptor blocker, steroids, MMF and statins reduced
end-organ damage often independent of reducing blood pressure
[14,17–19]. Thus we investigated whether relaxin is reducing
hypertensive target-organ damage in dTGR
Methods
Experiments were conducted in 4 week-old male age-matched
and body weight-matched transgenic rats harboring human renin
and angiotensinogen genes (dTGR) (Harlan, Netherlands) and
nontransgenic Sprague-Dawley rats (SD, Janvier, France). Local
authorities approved the studies (permit number: G0015/13) and
all procedures were done according to guidelines from the
American Physiological Society. All surgery was performed under
isoflurane anesthesia, and all efforts were made to minimize
suffering. Human recombinant relaxin was kindly provided by
Novartis, Switzerland and has been shown previously to be
bioactive in rodents [20].
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We compared untreated dTGR receiving vehicle (20 mM
sodium acetate, pH 5.0, n = 14), low dosage of relaxin (26 mg/kg
per day, n = 13), high dosage of relaxin (240 mg/kg per day,
n = 13), and SD control rats receiving vehicle (20 mM sodium
acetate, pH 5.0, n= 8) by subcutaneous osmotic minipump for 3
weeks. Treatments began when the rats were 4 weeks of age.
Systolic blood pressure was measured at week 5,6 and 7 by tail
cuff. Twenty-four-hour urine samples were collected in metabolic
cages also at week 5, 6 and 7. Urinary rat albumin was measured
with a commercially available ELISA (CellTrend, Germany).
Serum concentration of relaxin was also measured with a
commercially available ELISA (Immundiagnostik, Germany).
Serum cystatin C was measured with a commercially available
ELISA (BioVendor, Germany) and serum creatinine were
determined by an automated clinical method.
Rats were killed at age of 7 weeks. The kidneys and hearts were
washed with ice cold saline, blotted dry, and weighed. For gene
expression analysis, the tissues were snap-frozen in liquid nitrogen
and stored at 280uC. For immuno- and histochemistry, the tissues
were formalin fixed and paraffin embedded. Paraffin-embedded
sections were cut 4-6 mm thick and stained for collagens in heart
sections with Sirius red and in kidney sections with Masson’s
trichrome as described earlier [21,22]. Kindney sections were
incubated with primary monoclonal antibodies against rat
monocytes/macrophages (ED-1, 1:500; Serotec), and with Cy3
labelled secondary antibody against anti mouse (1:100; Jackson
Immuno Research). Semiquantitative scoring of ED-1-positive
cells was performed with use of a computerized cell count program
and described before in detail [18].
For quantitative RT-PCR, total mRNA was isolated with the
Qiagen RNeasy mini Kit (including the RNase-Free DNase set;
Qiagen) according to the manufacturer’s protocol from hearts and
kidneys of 7 week-old SD and dTGR animals. RNA was reverse
transcribed into cDNA by using the Transcriptor First Strand
cDNA synthesis kit from Roche Diagnostics and was analysed by
real-time quantitative PCR on ABI 7500 Fast sequence detection
system (PE Biosystems). Primer were designed with Primer Express
3.0 (Applied Biosystems) and synthesized by Biotez. Sequences are
listed in table S1. We analyzed the heart for brain natriuretic
peptide (BNP) and connective tissue growth factor (CTGF), and
the kidney for CTGF, neutrophil gelatinase-associated lipocalin
(NGAL) and nephrin.
All data are presented as means 6 SEM. Statistically significant
differences in mean values were tested by ANOVA and the
Tukey’s multiple range tests. A value of p,0.05 was considered
statistically significant.
Results
Systolic blood pressure increased progressively in vehicle-treated
dTGR from 16263 mm Hg in week 5 to 22565 mm Hg in week 7
(figure 1A). Relaxin treatment did not reduce blood pressure (low dose
20866 mmHg and high dose 22266 mmHg at week 7, respectively).
SD rats were normotensive (10661 mm Hg). Furthermore treatment
with relaxin (low dose 78.5616.8 mg/day and high dose 43.66
10.8 mg/day at week 7) did not ameliorate albuminuria compared to
vehicle-treated dTGR (57.93766.122 mg/day at week 7) (figure 1B).
Vehicle-treated and relaxin treated dTGR showed increased urinary
albumin excretion compared to SD (0.1460.06 mg/day at week 7).
Finally, relaxin treatment did not reduce mortality (figure 1C). Survival
was 52%, in vehicle-treated dTGR, it was 36% in low dose and 54%
high dose relaxin treated dTGRs at week 7. Treatment with
recombinant human relaxin led to serum concentrations that were
between 600 pg/ml and 1150 pg/ml after three weeks of treatment.
We detected no human relaxin in vehicle-treated dTGR (data not
shown).
Cardiac hypertrophy index (heart-to-body weight) of vehicle
treated (5.3860.13 mg/g) and relaxin-treated dTGR (low dose
5.2060.18 mg/g and high dose 5.3360.29 mg/g, respectively)
were significantly higher than in SD rats (2.9060.08 mg/g)
(figure 2A). Body weights of vehicle-treated and relaxin-treated
dTGR were not different. However, SD rats were heavier than
dTGR (data not shown). BNP and CTGF mRNA expression was
higher in vehicle-treated dTGR compared to SD rats (figure 2B
and 2C). There were no differences in BNP mRNA expression
between vehicle-treated and relaxin-treated dTGR. To examine
the extracellular matrix deposition, we used histological analysis of
Sirius red stained heart sections. Interstitial cardiac fibrosis was
present in heart sections of vehicle-treated dTGR rat (figure 3A).
Furthermore, Sirius red staining showed large stained areas
around the vessels of hearts from vehicle-treated dTGR indicating
perivascular cardiac fibrosis (figure 3B). Heart sections of relaxin-
treated dTGR showed the same interstitial and perivascular
cardiac fibrosis compared to vehicle-treated dTGR.
NGAL mRNA expression was significantly higher in vehicle-
treated dTGR compared to SD rats (figure 4A). There was no
difference in NGAL mRNA expression between vehicle-treated
and relaxin-treated dTGR. CTGF and nephrin mRNA expression
showed no significant changes between SD rats, vehicle-treated
Figure 1. Effect of relaxin on blood pressure, urinary albumin excretion, and survival. (A) Systolic blood pressure increased progressively
in vehicle-treated dTGR from week 5 to week 7. Relaxin treatment had no influence on blood pressure; SD rats were normotensive. (B) Vehicle-treated
dTGR showed significantly increased 24-hour urinary albumin excretion compared with control values. Relaxin did not eliminate the development of
albuminuria in dTGR. (C) Kaplan-Meier survival analysis of vehicle-treated dTGR and dTGR rats receiving low and high dose relaxin. By week 7, half of
untreated dTGR were dead. Relaxin did not improve survival of the dTGR. No controls died before end of study (data not shown).
doi:10.1371/journal.pone.0093743.g001
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and relaxin-treated dTGR (figure 4B and 4C). Masson trichrome
staining in the kidneys revealed that vehicle-treated dTGR had
increased matrix deposition (figure 5A). This matrix deposition
was also observed in kidney sections of relaxin-treated dTGR.
Renal macrophage and monocyte infiltration (ED-1 positive cells)
was significantly increased in untreated dTGR compared with SD
rats (figure 5B and S1). Again, relaxin treatment did not prevent
local macrophage and monocyte infiltration in the kidney. Serum
creatinine (figure 6A) and cystatin C (figure 6B) were significantly
increased in dTGR compared to controls. Both parameters were
not altered after administration of relaxin.
Discussion
Relaxin treatment had no influence on blood pressure, urinary
albumin excretion, or mortality in the dTGR model of hyperten-
sion-induced target-organ damage. Furthermore, no improvement
of cardiac hypertrophy and reduced matrix formation, as well as
connective tissue growth factor expression, was observed in the
heart of relaxin-treated dTGR animals. Relaxin also failed to
protect the kidney from Ang II-induced damage, as indicated by
the fact that relaxin did not ameliorate albuminuria and NGAL
expression, renal fibrosis, and inflammation. Most likely relaxin
did not improve the endorgan damage in this model, since blood
pressure, inflammation as well as profibrotic pathways in kidney
and heart were not improved by relaxin.
Relaxin has been evaluated in several acute heart failure (AHF)
trails in different cohorts of patients [6,7]. Pre-RELAX-AHF was a
double blind, multicenter, placebo-controlled randomized dose-
ranging study of relaxin in 234 AHF patients, enrolled within 16 h
after presenting with AHF [7]. Although not powered for
endpoints, marked improvement in dyspnea and resolution of
systemic and venous congestion was more observed in the group
receiving relaxin 30 mg/kg/day for 48 h. There was a significant
reduction in 180-day cardiovascular mortality in the relaxin group
(3% vs. 14.3% in the placebo group).
The inclusion criteria and definition of AHF were the same in
the RELAX-AHF study, as in the PRERELAX-AHF study [6].
The 1,161 subjects had a mean systolic blood pressure of
142 mmHg. Relaxin resulted in a greater SBP reduction both
Figure 2. Effect of relaxin on cardiac hypertrophy, BNP and CTGF expression. Treatment with relaxin did not attenuate the development of
cardiac hypertrophy (A) expressed as ratio of heart weight to body weight. Cardiac hypertrophy indices of vehicle-treated and treated dTGR rats were
significantly higher compared with nontransgenic SD rats. With RT-PCR, we examined BNP (B) and CTGF (C) mRNA expression in the heart. BNP and
CTGF mRNA expression was significant higher in vehicle-treated dTGR compared to SD rats. There were no differences in mRNA expression between
untreated and relaxin-treated dTGRs. mRNA levels of the target genes were normalized for the housekeeping gene 18S. Results are expressed as
mean 6 SEM of at least 5 animals per group.
doi:10.1371/journal.pone.0093743.g002
Figure 3. Cardial perivascular and interstitial fibrosis. Representative Sirius red stained heart section from a vehicle-treated and a relaxin-
treated dTGR rat. Heart sections of relaxin-treated dTGR showed the same interstitial (A) and perivascular (B) matrix deposition compared to vehicle-
treated dTGR animals. The upper panel shows a higher magnification.
doi:10.1371/journal.pone.0093743.g003
Relaxin and Ang II
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during and for 24 h after infusion. Consistent with previous
findings from PRERELAX AHF, there was a significant reduction
in cardiovascular death and all-cause mortality at 180 days in the
relaxin-treated group. Hernandez-Montfort studied patients with
ischemic heart disease and reduced ejection fraction. Their
patients were normotensive or hypertensive and had moderate
renal impairment [23].
The dTGR model has nothing in common with these clinical
studies. The severely hypertensive dTGR develop diastolic heart
failure and cachexia during young adulthood. The model is one of
fulminant target-organ damage [13]. The threshold dose of
recombinant human relaxin to achieve an increase renal function
in rats was 0.15 mg/h when given by subcutaneous osmotic
minipump [24]. The infusion rate of our low dose relaxin
treatment was 0.2 mg/h. This was close to the threshold dose and
therefore maybe at the lower therapeutic range. However high
dose of relaxin treatment had a 2 mg/h infusion rate, which should
be in an efficient range. Several studies were performed with a
higher dosage (4 mg/h) for a shorter duration (5–14 days) [25–29].
Since the dTGR rats at 3 weeks only weight around 90 g, the
highest concentration we could achieve was 2 mg/h. We cannot
exclude that a higher dosage was able to reduce cardiovascular
endorgan damage in this model. Furthermore we cannot exclude
that an earlier start of relaxin therapy has a positive effect on
endorgan damage. The dTGR pathology depends on the effects of
circulating and local Angiotensin II. Although we have shown in
earlier studies that anti-inflammatory therapies ameliorate renal
and cardiac endorgan damage, the effects can only be transferred
tot he human situation with caution. The pathology of the dTGR
Figure 4. NGAL, CTGF and nephrine expression in the kindney. NGAL mRNA expression (A) was significant higher in vehicle-treated dTGR
compared to SD rats. There were no differences in NGAL expression between vehicle-treated and relaxin-treated dTGR. CTGF (B) and nephrin (C)
mRNA expression showed no significant changes between SD rats, vehicle-treated and relaxin-treated dTGR. mRNA levels of the target genes were
normalized for the housekeeping gene 18S. Results are expressed as mean 6 SEM of 5 animals per group.
doi:10.1371/journal.pone.0093743.g004
Figure 5. Renal fibrosis and inflammation. Masson trichrome staining of kidney sections (A) showed increased matrix deposition in vehicle-
treated dTGR. Relaxin did not reduce matrix formation in the kidney (representative images). The upper panel shows a higher magnification. (B) Semi-
quantification of ED-1-positive cells in the kidney revealed that relaxin did not reduce monocyte/macrophage infiltration in kidney. At least fifteen
different areas of each kidney were analyzed. Results are mean 6 SEM of 4 animals per group.
doi:10.1371/journal.pone.0093743.g005
Relaxin and Ang II
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and the accelerated speed of the developing endorgan damage are
unique for this model.
The different pathways modulated by relaxin suggested that the
substance could be beneficial, especially the potent antifibrotic
properties exhibited by relaxin [2,30]. Relaxin inhibited fibroblast
proliferation, differentiation, collagen synthesis, collagen deposi-
tion, and increased MMP-2 expression, which most likely
contributed to an increase in collagen degradation and a decrease
in collagen deposition [2,30,31]. However, probably the hyper-
tension and the Ang II-induced inflammatory response are the
major hallmarks for the target-organ damage and stimulation of
the relaxin pathway was not sufficient to break this vicious circle
[15]. Beyond that the dTGR model is associated with impaired
endothelium-mediated vascular relaxation, whereas endothelium
independent vascular relaxation is unchanged [22]. Although
endothelial nitric oxide synthase (eNOS) expression in heart and
aorta were unchanged compared to controls (data not shown),
endothelial dysfunction might be due to uncoupled eNOS. Several
studies have shown that relaxin effects are endothelium and NO
dependent [20,32]. Thus, impaired endothelium mediated vascu-
lar relaxation in the dTGR model could explain the missing
relaxin effectiveness.
Recently Parikh et al. showed beneficial effects of relaxin on
atrial fibrillation in spontaneously hypertensive rats (SHR).
Relaxin treatment reversed the transcripts for fibrosis, increasing
conduction velocity, reduced electrophysiological abnormalities,
and reversed atrial hypertrophy [33]. In their study a one-week
therapy was ineffective in suppressing atrial fibrillation (AF) and
longer relaxin treatment was necessary. The authors speculate that
reversal of fibrosis is a slow process as a result of the slow collagen
turnover rate of around 5% per day in healthy hearts. The fibrosis
in our dTGR is much more pronounced [15]. This state-of-affairs
and the fact that fibrosis accelerates over time might be the reason
why relaxin was not successful in ameliorating target-organ
damage in dTGR [15].
We were also interested in the kidney in dTGR. Recently
Yoshida et al demonstrated that relaxin protected against
ischemia/reperfusion-induced renal injury by reducing apoptosis
and inflammation [29]. Relaxin also preserved renal function in
their model. Their relaxin dose, namely 500 ng/h was higher than
our high-dose. Moreover, the design of their study was based on
acute renal failure; our study was chronic in nature. Parikh et al
did not investigate inflammation, while Yoshida et al showed that
the TNFa receptor-1 was up regulated in the kidney and
normalized by relaxin [29,33]. We found no such effects in
dTGR model. The transcription factors nuclear factor-kB and
activator-protein 1 are strongly activated and responsible for the
sustained inflammatory and proliferative response in this model
[18,34]. Macrophages, dendritic cells and CD4 and CD8 T cells
are strongly activated. Surface adhesion molecule expression, such
as ICAM-1, VCAM-1, TNFa and interleukin-6, tissue factor
production, and activation of enzymes producing reactive oxygen
species are highly induced [13,17,19]. We speculate that relaxins
anti-inflammatory potential was not sufficient to counteract the
pro-inflammatory storm in dTGR.
In contrast to our findings, Lekgabe et al. showed that relaxin
reduced target-organ damage in spontaneous hypertensive rats
[35]. However, end-organ damage takes 9–10 months to develop
in that model and is far less severe than the effects reported here.
Relaxin, applied for 2 weeks, normalized fibrosis in heart and
kidney, inhibited cell and increased MMP-2 expression. Blood
pressure was not affected by relaxin treatment and mortality was
not investigated.
Wong et al investigated the effects of relaxin on fibrosis in
streptozotocin (STZ)-treated transgenic mRen-2 rats. That model
is also Ang II-mediated and features fairly severe changes. Relaxin
did not ameliorate glomerulopathy in this accelerated model of
type 1 diabetes [36]. Relaxin did not reduce hypertension or
albuminuria. Similar to our study, the authors were puzzled by the
negative results. The authors observed that relaxin was very
successful in reversing fibrosis when the TGF-b1 pathway was
activated and subsequently phosphorylation and down regulation
of smad-2 occurred [37]. This was not the case in the dTGR. We
noted earlier that protein expression levels of TGF-b were not
significantly upregulated in the dTGR [34]. By immunohisto-
chemistry, we showed that TGF-b remained unchanged in the
neointima and media of arterial blood vessels, as well as to
infiltrated cells perivascular and between cardiomyocytes.
Relaxin did not improve survival in a mouse model of coronary
artery ligation [38]. The two time-points chosen in that study
represented the important phases of the early and mature fibrotic
healing process. Although relaxin significantly inhibited the
progression of cardiac fibrosis in the mouse model, cardiac
function including fractional shortening was not improved.
Similarly, Xu et al investigated the effect of endogenous relaxin
on the development of cardiac hypertrophy, dysfunction, and
fibrosis after pressure overload using aortic constriction [39]. Rln
gene-deficient mice showed similar deterioration of cardiac
dysfunction and hypertrophy within 8 weeks after chronic pressure
overload, compared to Rln control mice.
We observed that relaxin did not alter blood pressure. This has
already been observed in SHR rats and after Ang II infusion [28].
In a short term experiment over 6 hours relaxin was able to
increase cardiac output and significantly decreased systemic
vascular resistance without changing mean arterial pressure in
both hypertensive rat models. The renal damage in dTGR is
most severe in the juxtamedullary cortex, leading to a direct
Figure 6. Creatinine and cystatin C serum concentrations.
Serum creatinine in vehicle-treated dTGR (A) was significantly elevated
at week 7 compared with SD. There were no differences in serum
creatinin concentration between vehicle-treated and relaxin-treated
dTGR. (B) Serum cystatin C in vehicle-treated dTGR was significantly
increased at week 7 compared with SD rats. Relaxin treatment did not
alter serum cystatin C concentration in dTGR animals. Results are
expressed as mean 6 SEM of at least 7 animals per group.
doi:10.1371/journal.pone.0093743.g006
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dependence on perfusion pressure [40]. This injury reduces the
autoregulation of renal blood flow which impairs an important
protective mechanism for the glomerulus [41]. Pressure variations
cannot be buffered, leading to further injury of the glomerular
capillaries with glomerulosclerosis and proteinuria. Relaxin
increases renal vasodilation and hyperfiltration in the rat by
reducing the myogenic reactivity in small renal arteries [31].
Relaxin promotes renal plasma flow and glomerular filtration rate,
thereby blunting the renal circulatory response to Ang II [42].
However, if hypertension persists and is not reduced, the
protective effects of relaxin could be harmful, leading to
progressive loss of autoregulation and increased pressure injury
in glomeruli [43]. Nevertheless the group of Conrad has
convincingly shown renal autoregulation remained intact in
pregnant rat although relaxin inhibited myogenic constriction of
renal interlobar arteries [44].
Conclusion
Recombinant relaxin is an exciting new avenue in clinical
medicine and could offer new therapeutic advances in patients
with AHF. Relaxin may provide a novel therapy for preeclampsia.
However, we could not show that relaxin is capable of reversing
Ang II-related effects in a fulminant model of Ang II-induced
target-organ damage.
Supporting Information
Figure S1 Immunohistochemistry of kidney tissue for
ED1-positive cells from SD, untreated and relaxin
treated dTGR rats. ED1, a marker of monocyte/macrophage
infiltration, showed prevalent inflammation in untreated dTGRs.
Relaxin treatments reduced monocyte/macrophage in-filtration in
the kidney.
(TIF)
Table S1 Primer sequences used for RT-PCR.
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